Quality of Life in Patients With Multiple Myeloma-validation Study
Validation of the Myeloma Patient Outcome Scale (MyPOS) Assessing the Quality of Life in Patients With Multiple Myeloma in the German Speaking Part of Switzerland
Sponsor: Celgene Corporation
Terminated
Not enough participants and study funding
Other terminated trials from Celgene Corporation
- Multiple Myeloma · Phase PHASE1/PHASE2 · Oct 2025
- Leukemia, Myeloid, Acute · Phase PHASE1 · Jul 2025
- Relapsed/Refractory Multiple Myeloma · Phase PHASE2 · Jul 2025
- Multiple Myeloma · Jun 2025
- Multiple Sclerosis · Phase PHASE3 · May 2025
More terminations from Celgene Corporation
This observational or N/A phase trial investigates Multiple Myeloma and is currently terminated or withdrawn. Celgene Corporation leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Nov 2021 — Jul 2024 [monthly]
Terminated
Status: Unknown Status → Terminated
-
Oct 2021 — Nov 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Recruiting
-
Jul 2019 — Sep 2019 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Jul 2019 [monthly]
Not Yet Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- Kantonsspital Aarau
- Kantonsspital Münsterlingen
- King's College London
- Klinik Hirslanden, Zurich
- Zurich University of Applied Sciences
For direct contact, visit the study record on ClinicalTrials.gov .